Neurobehavioral and immunological effects of prenatal cocaine exposure in rat.
Time-pregnant Sprague-Dawley rats were injected subcutaneously with 20 mg/kg of cocaine HCl or 0.9% saline daily from gestation days 15 through 21. Maternal plasma levels of approximately 720 ng/ml of cocaine did not alter maternal weight gain during treatment, duration of pregnancy, any of the litter variables or several indices of maternal behavior. Offsprings' body weight from birth to 30 days of age and physical maturation were not generally affected by prenatal cocaine exposure. While the development of surface righting, cliff avoidance, and the startle response was accelerated in cocaine-exposed offspring, acquisition of a preference for a social odor was unaltered. Prenatal cocaine also attenuated the locomotor response of the offspring to d-amphetamine and cocaine at PND 15; at PND 30 both of these catecholaminergic agonists increased activity in prenatal saline and prenatal cocaine offspring. However, the difference in plasma levels of cocaine at PND 30 suggests a possible down-regulation of adrenergic receptors following prenatal cocaine exposure. Decreased thymus/body weight ratios and splenomegaly were observed in prenatal cocaine animals at 55 days of age. Although complete neutralization of herpes simplex virus-type 1 was not observed, sera from prenatal cocaine offspring showed an increased rate of appearance of cytopathic effect, while sera from animals given cocaine postnatally showed a reduction in the rate at which viral infectivity was expressed in culture. These results indicate that prenatal cocaine exposure can alter neurobehavioral ontogeny and humoral immune responsitivity in the offspring.
Sobrian
S K
SK
Department of Pharmacology, Howard University College of Medicine, Washington, DC 20059.
Burton
L E
LE
Robinson
N L
NL
Ashe
W K
WK
James
H
H
Stokes
D L
DL
Turner
L M
LM
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D003042:Cocaine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D005865:Gestational Age; D007107:Immune System / Q000187:drug effects*; D008425:Maternal Behavior; D009043:Motor Activity / Q000187:drug effects*; D009929:Organ Size / Q000187:drug effects; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D051381:Rats; D011919:Rats, Inbred Strains; D012018:Reflex / Q000187:drug effects*; D018139:Simplexvirus; D013154:Spleen / Q000187:drug effects / Q000254:growth & development; D013950:Thymus Gland / Q000187:drug effects / Q000254:growth & development
D000914:Antibodies, Viral; D003042:Cocaine